Text Size

Effect of Advertisements on Treatment Compliance in Women With Breast Cancer

This study has been completed.
Sponsor:
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00462410
First received: April 18, 2007
Last updated: January 20, 2012
Last verified: May 2011
History of Changes
  Purpose

RATIONALE: Measuring how advertising affects treatment compliance in women with breast cancer may help doctors plan the best treatment.

PURPOSE: This clinical trial is studying how advertisements affect treatment compliance in women with breast cancer.


Condition Intervention
Breast Cancer
 Other: counseling intervention
Procedure: psychosocial assessment and care

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Health Services Research
Official Title: Socio-anthropological Study Evaluating the Impact of Observance or Treatment in Patients With Breast Cancer

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • Treatment compliance [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Factors affecting adherence to the medical plan [ Designated as safety issue: No ]

Estimated Enrollment: 65
Study Start Date: March 2006
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Detailed Description:

OBJECTIVES:

Primary

  • Evaluate the consequences of advertisement on treatment compliance in women with breast cancer.

Secondary

  • Determine the factors favoring or not favoring adherence to the medical recommendations.

OUTLINE: Patients and their medical and nonmedical caregivers are interviewed by a sociologist or anthropologist twice over 1 year. The first interview is at the consultation visit and the second interview is at the patient's home. The impact of advertisement on treatment compliance is measured.

PROJECTED ACCRUAL: A total of 65 patients will be accrued for this study.

  Eligibility

Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Diagnosis of breast cancer
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Female
  • Menopausal status not specified

PRIOR CONCURRENT THERAPY:

  • Not specified
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00462410

Sponsors and Collaborators
Institut Bergonié
Investigators
Study Chair: Marc Debled, MD Institut Bergonié
  More Information

Additional Information:
Clinical trial summary from the National Cancer Institute's PDQ® database  This link exits the ClinicalTrials.gov site

No publications provided

ClinicalTrials.gov Identifier: NCT00462410     History of Changes
Other Study ID Numbers: CDR0000540528, IB-2006-03, INCA-REF0145, INCA-SOCIO-ANTHROPO
Study First Received: April 18, 2007
Last Updated: January 20, 2012
Health Authority: United States: Federal Government

Keywords provided by National Cancer Institute (NCI):
recurrent breast cancer
stage I breast cancer
stage II breast cancer
stage IIIA breast cancer
 stage IIIB breast cancer
stage IIIC breast cancer
stage IV breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases

ClinicalTrials.gov processed this record on June 18, 2013